We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Delcath Systems Inc (DCTH) USD0.01

Sell:$10.95 Buy:$11.38 Change: $0.17 (1.52%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$10.95
Buy:$11.38
Change: $0.17 (1.52%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$10.95
Buy:$11.38
Change: $0.17 (1.52%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Contact details

Address:
566 Queensbury Avenue
QUEENSBURY
12804
United States
Telephone:
+1 (518) 7438892
Website:
https://delcath.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DCTH
ISIN:
US24661P8077
Market cap:
$350.43 million
Shares in issue:
31.97 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Gerard Michel
    Chief Executive Officer, Director
  • Martha Rook
    Chief Operating Officer
  • John Purpura
    Executive Vice President - Global Head of Operations
  • Sandra Pennell
    Senior Vice President - Finance, Chief Accounting Officer, Executive Officer
  • David Hoffman
    Chief Compliance Officer, General Counsel, Corporate Secretary
  • Kevin Muir
    General Manager, Interventional Oncology
  • Vojislav Vukovic
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.